Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15967632 | 0.90 | DDB1 (0.52) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL24515547 | 0.88 | ALDH1A1 (0.45) | ALDH1A1DDB1CRBN | |
| SCHEMBL15967642 | 0.88 | DDB1 (0.48) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL29046642 | 0.88 | ALDH1A1 (0.45) | ALDH1A1DDB1CRBN | |
| SCHEMBL15114687 | 0.84 | ALDH1A1 (0.50) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL29277621 | 0.81 | DDB1 (0.49) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL23956897 | 0.81 | DDB1 (0.49) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL28854721 | 0.80 | SMN1; SMN2 (0.56) | ALDH1A1KMT2A | |
| SCHEMBL10611467 | 0.79 | ALDH1A1 (0.45) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL16661304 | 0.79 | DDB1 (0.56) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274083-B2 | Substituted thiophenyl uracils, salts thereof and the use thereof as herbicidal agents | SYNGENTA CROP PROTECTION AG (CH) | 2022-03-15 | — | — | US | disclosed |
| EP-3728235-B1 | SUBSTITUTED THIOPHENYLURACILS , THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-02-09 | — | — | EP | disclosed |
| US-20210087151-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2021-03-25 | — | — | US | disclosed |
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274083-B2 | Substituted thiophenyl uracils, salts thereof and the use thereof as herbicidal agents | UNG, TYMP, TYMS | ALDH1A1 133/4885DDB1 303/4885CRBN 3221/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | ALDH1A1 3430/4885DDB1 430/4885CRBN 4226/4885 |
| US-20210087151-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | UNG, TYMP, TYMS | ALDH1A1 133/4885DDB1 303/4885CRBN 3221/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | ALDH1A1 3319/4885DDB1 142/4885CRBN 4367/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | ALDH1A1 3319/4885DDB1 142/4885CRBN 4367/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | ALDH1A1 3319/4885DDB1 142/4885CRBN 4367/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | ALDH1A1 3319/4885DDB1 142/4885CRBN 4367/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | ALDH1A1 793/4885DDB1 207/4885CRBN 4200/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | ALDH1A1 3734/4885DDB1 166/4885CRBN 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.